Eckert & Ziegler Strahlen und Medizintechnik (1EUZ) Price & Analysis

1 Followers

1EUZ Stock Chart & Stats

€15.67

€4.64(10.25%)

At close: Jan 07 4:00 PM EST

€15.67

€4.64(10.25%)

Day’s Range― - ―

52-Week Range€7.00 - €24.00

Previous CloseN/A

Volume0.00

Average Volume (3M)48.00

Market Cap

€842.25M

Enterprise Value€838.76

Total Cash (Recent Filing)€123.87M

Total Debt (Recent Filing)€43.27M

Price to Earnings (P/E)19.5

Beta0.92

Next Earnings

Aug 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.70

Shares Outstanding63,515,797

10 Day Avg. Volume40

30 Day Avg. Volume48

Financial Highlights & Ratios

PEG Ratio0.41

Price to Book (P/B)3.79

Price to Sales (P/S)3.06

P/FCF Ratio27.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.83

Revenue Forecast (FY)€323.00M

Bulls Say, Bears Say

Bulls Say

Strong Margins And ProfitabilitySustained high gross, operating and EBITDA margins indicate differentiated products and scale in radiopharmaceuticals. Such margin breadth supports durable earnings generation, reinvestment capacity and resilience to moderate volume swings over the next 2–6 months.

Conservative Balance Sheet And High ROELow leverage and strong returns on equity provide financial flexibility for capex, targeted investments or partnerships without stressing solvency. This capital conservatism reduces refinancing risk and supports durable strategic optionality in a regulated industry.

Structural Demand And Supply AdvantagesThe business supplies critical radioisotopes and services where reliability and compliance matter. Regulatory barriers and entrenched customer supply relationships create durable competitive advantages, supporting stable revenue streams and pricing power over medium term.

Bears Say

Weak Free Cash Flow ConversionFree cash flow covering only half of reported net income and showing a downtrend raises concern about earnings quality and internal funding capacity. Persistent weak conversion limits dividend, buyback or investment flexibility and increases reliance on working-capital or financing actions.

Profitability VolatilityA history of materially higher past net margins followed by normalization suggests sensitivity to product mix, pricing or cost swings. Such margin volatility complicates forward earnings predictability and planning for sustained reinvestment or shareholder returns.

Balance-sheet VariabilityShifts in total assets year-to-year indicate non-steady investment or working-capital patterns. This variability can translate into timing risk for cash flow and capital deployment, requiring closer monitoring of capex, inventory and receivables management.

Eckert & Ziegler Strahlen und Medizintechnik News

Eckert & Ziegler Strahlen und Medizintechnik (0NZY) Unveils Dividend Details for Q3: Mark Your Calendar!

Eckert & Ziegler Strahlen und Medizintechnik (LSE: 0NZY) has declared, under its dividend policy, a yearly cash dividend...

2y ago

1EUZ FAQ

What was Eckert & Ziegler Strahlen- und Medizintechnik AG’s price range in the past 12 months?

Eckert & Ziegler Strahlen- und Medizintechnik AG lowest stock price was €7.00 and its highest was €24.00 in the past 12 months.

What is Eckert & Ziegler Strahlen- und Medizintechnik AG’s market cap?

Eckert & Ziegler Strahlen- und Medizintechnik AG’s market cap is €842.25M.

When is Eckert & Ziegler Strahlen- und Medizintechnik AG’s upcoming earnings report date?

Eckert & Ziegler Strahlen- und Medizintechnik AG’s upcoming earnings report date is Aug 13, 2026 which is in 15 days.

How were Eckert & Ziegler Strahlen- und Medizintechnik AG’s earnings last quarter?

Eckert & Ziegler Strahlen- und Medizintechnik AG released its earnings results on May 12, 2026. The company reported €0.166 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Eckert & Ziegler Strahlen- und Medizintechnik AG overvalued?

According to Wall Street analysts Eckert & Ziegler Strahlen- und Medizintechnik AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Eckert & Ziegler Strahlen- und Medizintechnik AG pay dividends?

Eckert & Ziegler Strahlen- und Medizintechnik AG does not currently pay dividends.

What is Eckert & Ziegler Strahlen- und Medizintechnik AG’s EPS estimate?

Eckert & Ziegler Strahlen- und Medizintechnik AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Eckert & Ziegler Strahlen- und Medizintechnik AG have?

Eckert & Ziegler Strahlen- und Medizintechnik AG has 63,515,797 shares outstanding.

What happened to Eckert & Ziegler Strahlen- und Medizintechnik AG’s price movement after its last earnings report?

Eckert & Ziegler Strahlen- und Medizintechnik AG reported an EPS of €0.166 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.081%.

Which hedge fund is a major shareholder of Eckert & Ziegler Strahlen- und Medizintechnik AG?

Currently, no hedge funds are holding shares in IT:1EUZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Eckert & Ziegler Strahlen und Medizintechnik Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

1.61%

Trailing 12-Months

Asset Growth

5.51%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Eckert & Ziegler Strahlen- und Medizintechnik AG

Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services. It offers standard and radiation sources for medical and industrial sectors; medical imaging and spect diagnostics, industrial analytical and instrument, high activity CS-137 and CO-60, and oil well logging sources; blood irradiators and environmental disposal source services; and bulk isotopes as well as calibration-related sources for radioisotopes. In addition, the company offers Tc-99m generators and supplies, trade in raw isotopes and other products, and services. It serves medical, scientific, and industrial applications. The company was formerly known as Eckert & Ziegler Strahlen- und Medizintechnik AG and changed its name to Eckert & Ziegler SE in March 2024. Eckert & Ziegler SE was founded in 1992 and is headquartered in Berlin, Germany.